Search bioRxiv⌕ Search

Biology subjects

Nalvarte, I.

Publications and source records attributed to Nalvarte, I..

2 recordsLinked to original sources

Alzheimer's Disease Mutations Disrupt Neural Stem Cell Fate and Early Brain Development

Alzheimers disease (AD) has been largely considered as an age-related disease, mainly affecting mature or aging adult brain. Recent studies show that AD-associated mutations could impair early life, even during neurodevelopment. However, due to the complex of AD mutations and neurodevelopmental regulations, how mutations in specific genes affect the origin of neurodevelopment is still largely under studied. In this study, we investigate how AD mutations in App gene impact neurodevelopment, with a focus on NSC dynamics and the balance between neurogenesis and gliogenesis. We employed the 5xFAD transgenic line and the APPNL-G-F knock-in model, RNA sequencing, neurosphere assay and histological analyses on the cortex and hippocampus across critical developmental timepoints. Our results reveal that the APPNL-G-F model exhibits early gene expression changes, with suppressed stem cell proliferation, impaired neurogenesis, upregulation of gliogenesis and enhanced neuroinflammatory pathways. In contrast, the 5xFAD model displays minimal embryonic differences, with pronounced postnatal alterations likely driven by both gene mutations and APP overexpression. These findings indicate that AD mutations can inherently impair NSC self-renewal and differentiation, resulting in a suboptimal brain structure that have potentially higher vulnerability towards AD pathology in later life.

developmental biology↗

ERβ mediates sex-specific protection in the App-NL-G-F mouse model of Alzheimer's disease

Menopausal loss of neuroprotective estrogen is thought to contribute to the sex differences in Alzheimers disease (AD). Activation of estrogen receptor beta (ER{beta}) can be clinically relevant since it avoids the negative systemic effects of ER activation. However, very few studies have explored ER{beta}-mediated neuroprotection in AD, and no information on its contribution to the sex differences in AD exists. In the present study we specifically explored the role of ER{beta} in mediating sex-specific protection against AD pathology in the clinically relevant AppNL-G-F knock-in mouse model of amyloidosis, and if surgical menopause (ovariectomy) modulates pathology in this model. We treated male and female AppNL-G-F mice with the selective ER{beta} agonist LY500307 and subset of the females was ovariectomized prior to treatment. Memory performance was assessed and a battery of biochemical assays were used to evaluate amyloid pathology and neuroinflammation. Primary microglial cultures from male and female wild-type and ER{beta}-knockout mice were used to assess ER{beta}s effect on microglial activation and phagocytosis. We find that ER{beta} activation protects against amyloid pathology and cognitive decline in male and female AppNL-G-F mice. Ovariectomy increased soluble amyloid beta (A{beta}) in cortex and insoluble A{beta} in hippocampus, but had otherwise limited effects on pathology. We further identify that ER{beta} does not alter APP processing, but rather exerts its protection through amyloid scavenging that at least in part is mediated via microglia in a sex-specific manner. Combined, we provide new understanding to the sex differences in AD by demonstrating that ER{beta} protects against AD pathology differently in males and females, warranting reassessment of ER{beta} in combating AD.

neuroscience↗